SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-038253
Filing Date
2023-11-09
Accepted
2023-11-09 16:14:46
Documents
15
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eigr-20231109.htm   iXBRL 8-K 27604
2 EX-99.1 eigr-2023_novemberx9xexx991.htm EX-99.1 101129
6 image.jpg GRAPHIC 28424
7 image_991a.jpg GRAPHIC 16425
  Complete submission text file 0001628280-23-038253.txt   325219

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eigr-20231109.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eigr-20231109_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eigr-20231109_pre.xml EX-101.PRE 12510
9 EXTRACTED XBRL INSTANCE DOCUMENT eigr-20231109_htm.xml XML 2710
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 231392596
SIC: 2836 Biological Products, (No Diagnostic Substances)